Construction Materials

Suncrete

Suncrete to Release FY2026 Q1 Earnings on May 15 Pre-Market (EST), Forecast Revenue USD 60M, EPS USD 0.03

Suncrete released FY2025 9 Months Earnings on April 14 (EST), actual revenue USD 130.78 M, actual EPS USD -0.1411

Suncrete released FY2025 Annual Earnings on April 14 (EST), actual revenue USD 194.87 M, actual EPS USD -0.1165

Suncrete released FY2025 Q3 earnings on April 14 (EST), actual revenue USD 53.54 M, actual EPS USD -0.1662

Suncrete released FY2025 Q4 earnings on April 14 (EST), actual revenue USD 64.09 M, actual EPS USD -0.0765

Suncrete released FY2025 Q1 earnings on November 12, 2025 (EST) with actual revenue of USD 38.62 M and EPS of USD 0.0125

Suncrete released FY2024 Semi-Annual earnings on November 12, 2025 (EST), actual revenue USD 85.7 M, actual EPS USD 0

Suncrete released FY2023 Annual Earnings on November 12, 2025 (EST), with actual revenue of USD 144.28 M and EPS of USD 0

Suncrete released FY2024 Q1 earnings on November 12 (EST), actual revenue USD 42.85 M, actual EPS USD 0

Suncrete released FY2024 Q3 earnings on November 12, 2025 (EST), with actual revenue of USD 51.37 M and EPS of USD -1.0666

Suncrete released FY2024 Q4 earnings on November 12 (EST), actual revenue USD 46.25 M, actual EPS USD 0.7129

Suncrete released FY2025 Semi-Annual Earnings on November 12, 2025 (EST), Actual Revenue: USD 77.24 M, Actual EPS: USD 0.0251

Suncrete released FY2024 Annual Earnings on November 12, 2025 (EST), with actual revenue of USD 183.31 M and EPS of USD -0.4196

Suncrete released FY2024 Q2 earnings on November 12 (EST), actual revenue USD 42.85 M, actual EPS USD 0

Suncrete released FY2024 9 Months Earnings on November 12, 2025 (EST), with actual revenue of USD 137.06 M and actual EPS of USD -1.0666

Suncrete released FY2025 Q2 earnings on November 12 (EST), actual revenue USD 38.62 M, actual EPS USD 0.0125

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

MicroAlgo

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

RMIX

Suncrete (NASDAQ:RMIX) reported a 64% increase in Q1 revenue to $61.8 million during its first earnings call as a public company. The company outlined an acquisition-driven growth strategy, targeting expansion in the Sun Belt. Despite a net loss of $1.7 million, adjusted EBITDA rose 20% to $10.9 million. Suncrete's 2026 outlook projects revenue between $420 million and $480 million, with a focus on organic growth and recent acquisitions, including Hope Concrete and Nelson Bros. Ready Mix.

Market Beat

Suncrete Q1 Earnings Call Highlights

Earnings Watch

Suncrete | 8-K: FY2026 Q1 Revenue: USD 61.83 M

Suncrete, Inc. (RMIX) is set to release Q1 earnings on May 15, with expectations of 3 cents per share on $65 million revenue. The company recently acquired Nelson Bros. Ready Mix, LLC. Shares fell 0.7% to $17.50. Analysts from Roth Capital, William Blair, and Jefferies have initiated coverage with Buy and Outperform ratings, setting price targets between $19 and $21.

fidelity

Jefferies Financial

Top Wall Street Forecasters Revamp Suncrete Expectations Ahead Of Q1 Earnings

Analyst Ryan Merkel from William Blair has initiated a Buy rating for Suncrete Inc. (RMIX), citing its rollup strategy in the ready-mix concrete sector and strong demand from infrastructure and construction. The company is expanding through acquisitions in fast-growing Sunbelt metros, supported by federal funding and population growth in these states. Jefferies also recently issued a Buy rating with a $19.00 price target for the stock.

Tip Ranks

Analyst Initiates Suncrete Inc. With Buy Rating on Sunbelt Rollup Strategy and Robust Construction Demand Tailwinds

LFUS

CIEN

CVLT

ARWR

Top Wall Street analysts have initiated coverage on several companies, including Littelfuse Inc (LFUS) with a Buy rating and a price target of $450, Ciena Corp (CIEN) with a Neutral rating and a price target of $416, CommVault Systems (CVLT) with a Peer Perform rating, Arrowhead Pharmaceuticals (ARWR) with an Overweight rating and a price target of $88, and Suncrete (RMIX) with a Buy rating and a price target of $19. Analyst ratings reflect varied outlooks on these stocks as they traded at $408.98, $537.95, $99.82, $74.56, and $17.64 respectively on Friday.

benzinga_article

Littelfuse

Ciena

Commvault Systm

ArrowHead Pharma

This Littelfuse Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Suncrete shares are trading higher after Jefferies initiated its coverage on the stock with a Buy rating and announced a price target of $19.